Baseline Immunological Profile in Secondary Progressive Multiple Sclerosis Patients of Phase III EXPAND Trial

被引：0
|
作者：
Mao-Draayer, Yang [1 ]
Wu, Qi [1 ]
Wang, Qin [1 ]
Lundy, Steve K. [1 ]
Dowling, Catherine [1 ]
Segal, Benjamin Matthew M. [1 ]
Fox, David [1 ]
Wallstroem, Erik [2 ]
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Novartis Pharma AG, Basel, Switzerland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P011
引用
收藏
页码：12 / 12
页数：1
相关论文
共 50 条
  • [21] Immunological profile of patients with primary progressive multiple sclerosis -: Expression of adhesion molecules
    Durán, I
    Martínez-Cáceres, EM
    Río, J
    Barberá, N
    Marzo, ME
    Montalban, X
    BRAIN, 1999, 122 : 2297 - 2307
  • [22] Interferon inducible transcriptional profile in secondary progressive multiple sclerosis patients
    Gurevich, M.
    Miron, G.
    Hanael, E.
    Sonis, P.
    Dolev, M.
    Magalashvili, D.
    Achiron, A.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 176 - 176
  • [23] Uncoupling the Impact on Relapses and Disability Progression: Siponimod in Relapsing and Non-relapsing Patients With Secondary Progressive Multiple Sclerosis in the Phase III EXPAND Study
    Cree, Bruce
    Fox, Robert
    Giovannoni, Gavin
    Vermersch, Patrick
    Bar-Or, Amit
    Gold, Ralf
    Magnusson, Baldur
    Rouyrre, Nicolas
    Meier, Daniela Piani
    Tomic, Davorka
    Karlsson, Goeril
    Dahlke, Frank
    Kappos, Ludwig
    NEUROLOGY, 2018, 90
  • [24] Effect of Siponimod on Cognition in Patients with Secondary Progressive Multiple Sclerosis (SPMS): Phase 3 EXPAND Study Subgroup Analysis
    Benedict, Ralph
    Fox, Robert
    Tomic, Davorka
    Cree, Bruce
    Vermersch, Patrick
    Giovannoni, Gavin
    Bar-Or, Amit
    Gold, Ralf
    Ritter, Shannon
    Karlsson, Goeril
    Wolf, Christian
    Kappos, Ludwig
    NEUROLOGY, 2019, 92 (15)
  • [25] The EXPAND study results: Efficacy of siponimod in secondary progressive multiple sclerosis
    Vermersch, P.
    Bar-Or, A.
    Cree, B.
    Fox, R.
    Giovannoni, G.
    Gold, R.
    Arnould, S.
    Wallstroem, E.
    Sidorenko, T.
    Wolf, C.
    Dahlke, F.
    Kappos, L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 44 - 44
  • [26] Oral teriflunomide in patients with relapsing multiple sclerosis: baseline clinical features of patients in the TEMSO phase III trial
    O'Connor, Paul
    Confavreux, Christian
    Comi, Giancarlo
    Kappos, Ludwig
    Wolinsky, Jerry
    Olsson, Tomas P.
    Miller, Aaron
    Freedman, Mark S.
    MULTIPLE SCLEROSIS, 2008, 14 : S85 - S85
  • [27] FACTORS INFLUENCING HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS USING EXPAND TRIAL DATA
    Vadapalle, S.
    Vudumula, U.
    Gudala, K.
    Adlard, N. E.
    VALUE IN HEALTH, 2019, 22 : S755 - S755
  • [28] Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis (SPMS): baseline characteristics of the EXPAND study population
    Kappos, L.
    Bar-Or, A.
    Cree, B.
    Fox, R.
    Giovannoni, G.
    Gold, R.
    Vermersch, P.
    Bhasin, P.
    Arnould, S.
    Sidorenko, T.
    Wallstroem, E.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 317 - 318
  • [29] Mitoxantrone in progressive multiple sclerosis: MRI results of the European Phase III trial
    Krapf, H
    Morrissey, SP
    Zenker, O
    Zwingers, T
    Gonsette, R
    Hartung, HP
    NEUROLOGY, 1999, 52 (06) : A495 - A495
  • [30] The Pharmacokinetics of Lipoic Acid at Baseline and 48 Weeks in Secondary Progressive Multiple Sclerosis Patients
    Bittner, Frank
    Murchison, Charles
    Bourdette, Dennis
    Spain, Rebecca
    ANNALS OF NEUROLOGY, 2016, 80 : S117 - S117
12345